Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell membranes and extracellular biomolecules represent a broad structural and functional category rather than a single, discrete therapeutic target. The cell membrane is a complex phospholipid bilayer that serves as a selective barrier and a platform for signaling proteins, while extracellular biomolecules encompass the proteins, glycosaminoglycans, and other factors within the extracellular matrix (ECM) and interstitial fluid (Alberts B, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002). Pharmacological intervention in this category often involves the use of antibiotics like Polymyxin B, which disrupts bacterial membranes, or enzymes like hyaluronidase that modify the ECM to improve drug delivery (StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554480/; PubChem CID 5360371). Because this grouping includes a vast array of unrelated molecules and structures, it is generally considered too broad for specific drug development programs, which instead focus on individual receptors or enzymes within these environments (Lu P, et al. J Cell Biol. 2012;196(4):395-406). Targeting these structures carries risks of off-target toxicity due to the ubiquitous nature of membranes and the essential structural roles of the ECM in healthy tissues (PubMed, PMID: 22351925). Consequently, while these components are vital to physiology and are affected by various drugs, they do not constitute a single "target" in the conventional sense of molecular pharmacology.
Drugs targeting these structures typically work by disrupting the physical integrity of the lipid bilayer, altering membrane permeability, or enzymatically degrading components of the extracellular matrix to facilitate tissue penetration or modify signaling environments (StatPearls, 'Polymyxin B'; Lu P, et al. J Cell Biol. 2012).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell membranes and extracellular biomolecules.